Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Lian YuJianlin XuRong QiaoBao-Hui HanHua ZhongRunbo ZhongPublished in: Cancer medicine (2022)
The combination of anlotinib and PD-1/PD-L1 blockade has promising efficacy and safety as a second-line or subsequent therapy for SCLC.